LONDON – Oncimmune Holdings plc has won government funding to apply its autoantibody biomarker technology to develop a COVID-19 immune profiling tool for triaging patients and predicting response to therapies and vaccines in development against the virus. The company will cross reference serum samples from 3,000 COVID-19 patients against its library of 800 SARS-CoV-2 related antigens and peptides to identify autoantibodies that characterize the range of immune responses to the infection.